Investigational drug · Phase 2
AK120
Also called: JAK inhibitor users need to double the initial dose
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
9
Any phase or sponsor naming "AK120"
First trial start
2024
Jul 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK120" as an intervention, largest first.
AkesoIndustry
NCT06700499 · 450 participants · Start Jul 8, 2024 · Primary completion Jul 31, 2025
Drug: AK120 300mg Q2W (JAK inhibitor users need to double the initial dose) · For: Atopic Dermatitis
Sites: Beijing, China; Fuzhou, China; Xiamen, China · 50 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic DermatitisPivotal-lookingCompleted
AkesoIndustry
NCT06035354 · 427 participants · Start Nov 3, 2021 · Primary completion Jun 21, 2024
Drug: AK120; AK120 and 8 more · For: Atopic Dermatitis
Sites: Bengbu, China; Wuhu, China; Beijing, China · 39 sites in all
- A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic DermatitisPivotal-lookingStatus unknown
AkesoIndustry
NCT06383468 · 420 participants (planned) · Start Apr 30, 2024 · Primary completion Jan 30, 2025
Drug: AK120 · For: Atopic Dermatitis
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 59 sites in all
- A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic DermatitisPivotal-lookingNot yet recruiting
AkesoIndustry
NCT06767540 · 198 participants (planned) · Start Jan 23, 2025 · Primary completion Jul 10, 2027
Drug: Placebo; placebo · For: Atopic Dermatitis
Sites: Wuhu, China; Beijing, China; Chongqing, China · 28 sites in all
- A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
AkesoIndustry
NCT06092762 · 180 participants · Start Nov 6, 2023 · Primary completion Nov 13, 2024
Drug: AK120 · For: Atopic Dermatitis
Sites: Hefei, China; Beijing, China; Xiamen, China · 26 sites in all
Akesobio Australia Pty LtdIndustry
NCT04256174 · 80 participants · Start Jun 15, 2020 · Primary completion Oct 29, 2021
Drug: AK120 or placebo- Part 1- Cohort 1; AK120 or placebo- Part 1- Cohort 2 and 7 more · For: Atopic Dermatitis
Sites: Botany, Australia; Camberwell, Australia; Adelaide, Australia · 13 sites in all
- Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic DermatitisTerminated
Akesobio Australia Pty LtdIndustry
NCT05048056 · 79 participants · Start Sep 30, 2021 · Primary completion May 17, 2023
Drug: Placebo; AK120 and 1 more · For: Atopic Dermatitis
Sites: Little Rock, Arkansas; Canoga Park, California; San Diego, California · 24 sites in all
- A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)Not yet recruiting
AkesoIndustry
NCT06756126 · 24 participants (planned) · Start Dec 30, 2024 · Primary completion Jun 30, 2025
Drug: AK120 · For: Atopic Dermatitis
Sites: Dongguan, China; Guangzhou, China; Shenzhen, China · 6 sites in all
AkesoIndustry
NCT05155020 · 1 participants · Start Feb 11, 2022 · Primary completion Aug 5, 2022
Drug: AK120; AK120 and 2 more · For: Asthma
Sites: Hefei, China; Beijing, China; Guangzhou, China · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of IL-4Rα Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials.
Vieira ACP, de Freitas Rezende E, de Jesus ACVS, et al. · Australas J Dermatol 2026
- Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Wynne CJ, Cole A, Lemech C, et al. · Dermatol Ther (Heidelb) 2023
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.